Trabectedin for advanced soft tissue sarcomas: optimizing use

Figures & data

Figure 1 The chemical structure of trabectedin.

Table 1 Phase II studies of single-agent trabectedin in advanced soft tissue sarcomas

Reference	Line of therapy	Pt no	Dose schedule	Response rate	6-month PFS	Median duration of survival
^Citation14	Second or third	270	Randomized study – 1.5 mg/m^2 24-hour infusion q3w versus 0.58 mg/m^2 3-hour infusion once weekly, 3 out of 4 wks	5.6% (24-hour infusion q3w)	35.5% (24-hour infusion q3w)	13.9 versus 11.8 months (HR 0.843; 95% CI, 0.653–1.090; P=0.1920) for 24- versus 3-hour schedule
^Citation25	Second, third, and fourth	36	1.5 mg/m^2 24-hour infusion q3w	8%	Not described. Median TTP 1.7 months (95% CI, 1.3–4.4 months) 1-year survival rate 53%	12.1 months (95% CI 8.1–26.5 months)
^Citation26	Second or third	104	1.5 mg/m^2 24-hour infusion q3w	8%	29%	9.2 months (278 days; 95% CI 238–368)
^Citation27	First	36	1.5 mg/m^2 24-hour infusion q3w	17%	24.4% (95% CI, 13–44)	Not documented
^Citation32	Second, third, or fourth	54	1.5 mg/m^2 24-hour infusion q3w	4%	24%	12.8 months (range, 0.69–33.77 months)

Abbreviations: PFS, progression free survival; TTP, time to progression; q3w, 3 weekly; pt no, patient number; HR, hazard ratio; CI, confidence interval.

DemetriGDChawlaSPvon MehrenMEfficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedulesJ Clin Oncol200927254188419619652065

 PubMed Web of Science ®Google Scholar

Martin-BrotoJLopez-PousaAGarcia del MuroXRandomised phase II trial of doxorubicin versus trabectedin plus doxorubicin in first line treatment of patients with advanced non-resectable or metastatic soft tissue sarcomas: a Spanish Group for Sarcoma Research (GEIS) studyEur Cancer Congr. (17 ECCO-38 ESMO-32 ESTRO)2013 Sep 27–Oct 1Amsterdam

 Google Scholar

Publicado en:Eur J Cancer201349suppl 2S875 Abstr.3800

 PubMedGoogle Scholar

Garcia-CarboneroRSupkoJGManolaJPhase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapyJ Clin Oncol20042281480149015084621

 PubMed Web of Science ®Google Scholar

Le CesneABlayJYJudsonIPhase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trialJ Clin Oncol200523357658415659504

 PubMed Web of Science ®Google Scholar

PenelNDemetriGDBlayJYGrowth modulation index as metric of clinical benefit assessment among advanced soft tissue sarcoma patients receiving trabectedin as a salvage therapyAnn Oncol201324253754223117071

 PubMed Web of Science ®Google Scholar